# Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis

## TL;DR

This paper discusses the use of Sodium-Glucose Cotransporter 2 Inhibitors in treating metabolic dysfunction-associated steatohepatitis.

## Contribution

The study introduces specific criteria for evaluating treatment outcomes in MASH patients using SGLT2 inhibitors.

## Key findings

- MASH improvement is defined by a decrease in NAS score with no fibrosis worsening.
- MASH resolution requires absence of hepatocellular ballooning and minimal inflammation.
- Fibrosis improvement is marked by a stage reduction without MASH worsening.

## Abstract

MASH denotes metabolic dysfunction‐associated steatohepatitis. MASH improvement was defined as a decrease in the non‐alcoholic fatty liver disease activity score (NAS) of ≥ 2 points or NAS ≤ 3 at week 48 after treatment, with no worsening of fibrosis (i.e., no increase in fibrosis stage). MASH resolution was defined as a hepatocellular ballooning score of 0 and a lobular inflammation score of 0 or 1 at week 48, with no worsening of fibrosis. Fibrosis improvement was defined as a reduction in fibrosis of ≥ 1 stage at week 48, with no worsening of MASH (i.e., no increase in steatosis, ballooning, or inflammation scores).